Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 12/20 | 0.34 |
| ▸ | HSP90B1 | P14625 | 4/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | ACE | P12821 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30790816 | 0.90 | DPP8 (0.36) | HSP90AA1HSP90B1NAMPT | |
| SCHEMBL31484847 | 0.85 | CDK4 (0.33) | CDK4CDK2CDK6HSP90AA1HSP90B1 | |
| SCHEMBL30790814 | 0.84 | SYK (0.36) | HSP90AA1HSP90B1NAMPT | |
| SCHEMBL31484851 | 0.84 | SYK (0.36) | HSP90AA1HSP90B1NAMPT | |
| SCHEMBL30790842 | 0.84 | PDE10A (0.35) | CDK4CDK2CDK6HSP90AA1HSP90B1 | |
| SCHEMBL30790869 | 0.84 | DPP8 (0.38) | CDK4CDK2CDK6HSP90AA1HSP90B1 | |
| SCHEMBL30790838 | 0.82 | KCNH2 (0.38) | CDK4HSP90AA1HSP90B1 | |
| SCHEMBL30790817 | 0.81 | KEAP1 (0.47) | — | |
| SCHEMBL30790826 | 0.81 | MAP3K5 (0.36) | CDK4CDK2CDK6HSP90AA1CDK1 | |
| SCHEMBL30790810 | 0.80 | FLT3 (0.38) | CDK4CDK2CDK6CDK1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001876-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2026-01-01 | — | — | US | claimed |
| EP-4572761-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | claimed |
| WO-2024038129-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2024-02-22 | — | — | WO | claimed |
| US-20260001876-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2026-01-01 | — | — | US | disclosed |
| EP-4572761-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024038129-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001876-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE4B, PDE7A | CDK4 1396/4885CDK2 1728/4885CDK6 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.